Cardiac glycosides display selective efficacy for STK11 mutant lung cancer


Although STK11 (LKB1) mutation is a major mediator of lung cancer progression, targeted therapy has not been implemented due to STK11 mutations being loss-of-function. Here, we report that targeting the Na(+)/K(+)-ATPase (ATP1A1) is synthetic lethal with STK11 mutations in lung cancer. The cardiac glycosides (CGs) digoxin, digitoxin and ouabain, which… (More)
DOI: 10.1038/srep29721

6 Figures and Tables


  • Presentations referencing similar topics